T-VEC’s action was validated through a phase III, multicenter, open-label, randomized clinical trial known as OPTiM, which compared T-VEC to GM-CSF in patients with advanced melanoma that was not able to be removed surgically. The aim of the study was to determine durable response rate, defined as the percentage of patients with a complete or partial response maintained continuously for at least six months. Out of 436 patients enrolled in the study, 16.3 percent treated with T-VEC achieved a durable response compared to 2.1 percent treated with GM-CSF. Of those who had a durable response, 29.1 percent had a complete response, while 70.8 percent had a partial response.”
For the complete story click here: http://cinj.org/viral-therapy-melanoma-clinical-trial-led-rutgers-cancer-institute-physician-scientist-approved-fda.